Sernova Corp.

TSX:SVA.TO

Biotechnology

Healthcare
$0.14 -5.88%

-$0.01 today

Market cap
$50.98M
Beta
0.66
P/E (TTM)
-4.7
EPS (TTM)
-$0.03
52W Low $0.12High $0.21

Volume 0.55M

Average 0.12M

SVA.TO Interest Expense

Cost of servicing the company's debt during the period.

Sernova Corp.TSX: SVA.TO

Interest Expense · Q2 FY2026 · quarter ended Apr 2026

Interest expense growth accelerates

Q2 FY2026 interest expense of CA$920.95K rose 285.8% year over year, ahead of the +63.2% change in trailing-twelve-month interest expense. Sequentially, it rose 93.0% from the prior quarter. Over 3 fiscal years it compounded at +85.6% a year.

Context

  • Interest expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +285.8% holds above the trailing-twelve-month pace of +63.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
CA$920.95K+93.0% QoQ
Last fiscal yearOct 2025
CA$754.81K+28.6% YoY
LTMApr 2026
CA$1.68M+63.2% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+285.8%——
1 year+28.6%——
3-year CAGR+85.6%——
5-year CAGR——
10-year CAGR——

Interest Expense history

CAD · from the income statement

Latest · FY2025
754.81K CAD
Year-over-year change
+28.6%
4-year CAGR
+89.6%

Interest Expense vs competitors

How SVA.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +63.2% is the highest of 2, against a peer median of -19.9%.
  • Over three fiscal years its annual growth of +85.6% compares with a peer median of +236.9%.
SVA.TO Competitors
Interest Expense for SVA.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SVA.TOSernova Corp.LTM Apr 2026CA$1.68M CAD+63.2%+85.6%—
BCT.TOBriaCell Therapeutics Corp.LTM Apr 2026$29.63K USD-19.9%+236.9%—
Peer median (excluding SVA.TO) —-19.9%+236.9%—

Competitors are the stored peer set for SVA.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Revenue00000
Cost of Revenue267.2K440K445.55K540.28K342.59K
Gross Profit(267.2K)(440K)(445.55K)(540.28K)(342.59K)
Gross Margin—————
Research & Development4.64M16.9M32.26M22.36M7.28M
Selling, General & Admin2.29M7.83M8.46M8.97M7.5M
Operating Expenses6.94M24.75M41.13M31.84M14.78M
Depreciation & Amortization267.2K440K308.49K410.53K342.59K
EBITDA(6.6M)(24.54M)(40.19M)(31.25M)(14.74M)
EBITDA Margin—————
Operating Income(6.87M)(24.18M)(41.13M)(31.84M)(15.12M)
Operating Margin—————
Interest Income70.55K577.29K1.5M388.39K25.63K
Interest Expense58.37K118K32.08K586.86K754.81K
Other Income / Expenses1.09M1.01M1.5M(347.04K)(711.01K)
Income Before Tax(6.97M)(24.42M)(39.63M)(32.19M)(15.84M)
Pre-Tax Margin—————
Income Tax Expense58.37K118K(629.02K)7K(92.19K)
Net Income(7.02M)(24.54M)(39M)(32.19M)(15.74M)
Net Margin—————
EPS (Basic)(0.03)(0.09)(0.13)(0.10)(0.05)
EPS (Diluted)(0.03)(0.09)(0.13)(0.10)(0.05)
Weighted Avg Shares245.52M273.59M303.33M306.96M328.29M
Weighted Avg Shares (Diluted)245.52M273.59M303.33M306.95M328.29M

Sernova Corp.

TSX:SVA.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.